Pharma: Clinic Roundup
Thursday, January 24, 2013
Teva Pharmaceutical Industries Ltd., of Jerusalem, said top-line results of its Phase III program testing narcolepsy drug Nuvigil (armodafinil) as adjunct therapy in adults with major depression associated with bipolar I disorder showed that the drug produced a numerical improvement but did not reach statistical significance in meeting its primary endpoint determining whether armodafinil treatment, at a dosage of 150 mg per day, is more effective than placebo as adjunct therapy to mood stabilizers and/or atypical antipsychotics.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.